Merus's 15min chart signals MACD Death Cross and KDJ Death Cross.

Merus's 15-minute chart has exhibited a significant technical signal, with the MACD Death Cross and KDJ Death Cross both triggered on October 8th, 2025 at 13:00. This indicator suggests that the stock price has the potential to continue trending downward, as the momentum of the stock price is shifting towards the downside. As a result, there is a potential for further decreases in the stock price.

Genmab A/S (NASDAQ: GMAB) has seen its stock price target increased by Truist Securities, reflecting the potential benefits of the company's proposed acquisition of Merus N.V. (NASDAQ: MRUS). The investment firm raised its price target on Genmab to $49.00 from $46.00, maintaining a Buy rating Truist Securities raises Genmab stock price target to $49 on Merus acquisition^[1].

The acquisition, valued at approximately $8 billion, grants Genmab full rights to petosemtamab, an EGFR × LGR5 bispecific antibody currently in Phase 3 trials for head and neck cancer. Truist Securities views petosemtamab as a potential blockbuster asset that could offset the expected future decline in Darzalex royalties for Genmab. The firm projects that petosemtamab could contribute $1.8 billion to Genmab’s topline by 2029, or $1.45 billion on a risk-adjusted basis Truist Securities raises Genmab stock price target to $49 on Merus acquisition^[1].

Technical indicators also suggest a potential downward trend for Merus, with both the MACD Death Cross and KDJ Death Cross triggered on October 8, 2025, at 13:00 . This indicates a shift in momentum towards the downside, potentially leading to further decreases in the stock price. However, this technical analysis should be considered alongside fundamental data.

Other analysts have also adjusted their price targets following the acquisition announcement. H.C. Wainwright raised its target from $36 to $40, TD Cowen increased its target from $24 to $32, and Leerink Partners raised its target from $32 to $34 Truist Securities raises Genmab stock price target to $49 on Merus acquisition^[1]. The completion of the deal is expected by the first quarter of 2026, funded through cash and non-convertible debt financing.